|
| 36944408 | Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel. | J Mol Diagn | 2023 |
| 35078243 | ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications. | J Natl Cancer Inst | 2022 |
| 35444283 | CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition. | Nature | 2022 |
| 35830811 | Guiding ATR and PARP inhibitor combinationswith chemogenomic screens. | Cell Rep | 2022 |
| 34911817 | RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors. | Mol Cancer Ther | 2022 |
| 35121901 | The CIP2A-TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer. | Nat Cancer | 2021 |
| 33795234 | Synthetic Lethality in Cancer Therapeutics: The Next Generation. | Cancer Discov | 2021 |
| 32297743 | Discovery of (2<i>R</i>)-<i>N</i>-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1<i>H</i>-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. | J Med Chem | 2020 |
| 31699827 | AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. | Clin Cancer Res | 2020 |
| 32988967 | AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. | Clin Cancer Res | 2020 |
| 29636547 | BRD4 facilitates replication stress-induced DNA damage response. | Oncogene | 2018 |
| 29856615 | Discovery and Optimization of a Novel Series of Highly Selective JAK1 Kinase Inhibitors. | J Med Chem | 2018 |
| 30036377 | BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. | PLoS One | 2018 |
| 30297535 | Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer. | Cancer Res | 2018 |
| 30335946 | Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. | ACS Chem Biol | 2018 |
| 28615361 | Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. | Sci Transl Med | 2017 |
| 28371485 | Target Deconvolution Efforts on Wnt Pathway Screen Reveal Dual Modulation of Oxidative Phosphorylation and SERCA2. | ChemMedChem | 2017 |
| 29245897 | Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum. | Oncotarget | 2017 |
| 29212548 | Generation of stable PDX derived cell lines using conditional reprogramming. | Mol Cancer | 2017 |
| 27025877 | JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. | Sci Signal | 2016 |
| 26614408 | Identification of azabenzimidazoles as potent JAK1 selective inhibitors. | Bioorg Med Chem Lett | 2016 |
| 27472462 | Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. | Oncotarget | 2016 |
| 27472392 | Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation. | Oncotarget | 2016 |
| 27573426 | AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies. | Mol Cancer Ther | 2016 |
| 27189703 | Next-generation sequencing identifies a novel ELAVL1-TYK2 fusion gene in MOLM-16, an AML cell line highly sensitive to the PIM kinase inhibitor AZD1208. | Leuk Lymphoma | 2016 |
| 25537515 | Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers. | Oncotarget | 2015 |
| 26351323 | Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. | Mol Cancer Ther | 2015 |
| 25779944 | The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models. | Clin Cancer Res | 2015 |
| 24462666 | Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-ε kinases. | Bioorg Med Chem Lett | 2014 |
| 24577942 | Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. | Mol Cancer Ther | 2014 |
| 24359159 | Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. | J Med Chem | 2014 |
| 23562594 | Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target. | Bioorg Med Chem Lett | 2013 |
| 23942095 | Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer. | Clin Cancer Res | 2013 |
| 22305584 | Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases. | Bioorg Med Chem Lett | 2012 |
| 21138246 | Discovery of 5-chloro-N2-[(1S)-1-(5-fluoropyrimidin-2-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (AZD1480) as a novel inhibitor of the Jak/Stat pathway. | J Med Chem | 2011 |
| 21920898 | Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. | Cancer Res | 2011 |
| 21493067 | In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. | Bioorg Med Chem Lett | 2011 |
| 20144546 | Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors. | Bioorg Med Chem Lett | 2010 |
| 19112018 | Identification of 3-amido-4-anilinoquinolines as potent and selective inhibitors of CSF-1R kinase. | Bioorg Med Chem Lett | 2009 |
| 19857966 | Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors. | Bioorg Med Chem Lett | 2009 |
| 19962667 | The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. | Cancer Cell | 2009 |
| 18775810 | Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. | J Biol Chem | 2008 |
| 11162641 | Ceramide induces the dephosphorylation and inhibition of constitutively activated Akt in PTEN negative U87mg cells. | Biochem Biophys Res Commun | 2001 |
| 11489829 | AKT-1, -2, and -3 are expressed in both normal and tumor tissues of the lung, breast, prostate, and colon. | Clin Cancer Res | 2001 |
| 9808785 | The histidine kinase dhkC regulates the choice between migrating slugs and terminal differentiation in Dictyostelium discoideum. | Dev Biol | 1998 |
| 9576830 | The hybrid histidine kinase dhkB regulates spore germination in Dictyostelium discoideum. | Dev Biol | 1998 |